---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-015295"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:27:18.306083+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# 60 Degrees Pharmaceuticals sponsors pre-clinical study of tafenoquine against Candida auris with Monash University

## Summary
- Animal studies will test tafenoquine efficacy against Candida spp, including drug-resistant Candida auris.
- Monash University conducts studies; experiments start May 2024, completion by Nov 30, 2024.
- Company to pay Monash $90,167 AUD on April 1, 2024 and $90,167 AUD on service completion.
- Tafenoquine is FDA-approved for malaria prophylaxis; its antifungal mode of action is differentiated from standard care.
- Results expected by end of 2024; earlier in vitro data showed broad-spectrum antifungal activity.

## SEC filing metadata
- accession: 0001213900-24-015295
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390024015295/0001213900-24-015295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390024015295/ea0200322-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-015295
- JSON: https://secwatch.observer/filing/0001213900-24-015295.json
- Plain text: https://secwatch.observer/filing/0001213900-24-015295.txt

## Key facts
- Material Agreements
  60 DEGREES PHARMACEUTICALS, INC. entered into Research Services Agreement with Monash University valued at $90,167 AUD on April 1, 2024 and $90,167 AUD upon the completion of the Services (effective 2024-02-05).
  - Action: entry
  - Counterparty: Monash University
  - Value: $90,167 AUD on April 1, 2024 and $90,167 AUD upon the completion of the Services
  - Effective: 2024-02-05
  source text: On February 13, 2024, 60 Degrees Pharmaceuticals, Inc.’s (the “Company”) majority-owned Australian subsidiary, 60P Australia Pty Ltd, and Monash University entered into the Research Services Agreement (the “Agreement”) in which Monash University agreed to provide research services, including among other things, testing the efficacy of tafenoquine against candidemia, confirming suitable fungal infection dosage and determining the pharmacokinetics of tafenoquine following intraperitoneal drug administration (collectively, the “Services”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1946563/000121390024015295/0001213900-24-015295-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.